Tag: updates

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Prime Medicine, Inc.

Prime Medicine, Inc.

Maturing into clinical-stage company; on-track to file IND application or CTA for PM359 in 1H 2024, with initial data expected in 2025 —

— Progressing broader portfolio across core areas of focus; expect to initiate IND-enabling activities in first liver and ocular disease programs in 2024 —

— Advancing hotspot and PASSIGE™ Prime Editors for CF following entry into therapeutic development agreement with Cystic Fibrosis Foundation —

— Completed upsized $161 million public offering —

CAMBRIDGE, Mass., March 01, 2024 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2023 and provided a business update.

“In 2024, we anticipate undergoing a significant transformation, maturing into a clinical-stage company and bringing the first-ever Prime Editing-based therapeutic candidate to patients. We look forward to filing our first IND or CTA in the months ahead, and to commencing our Phase 1 clinical trial in CGD, a serious, life-threatening disease that we believe is uniquely suited for treatment with a Prime Editing-based approach,” said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine. “In parallel, we continue to progress our broader pipeline, where we are advancing programs across our core areas of focus: hematology and immunology, liver, lung, ocular and neuromuscular disease. This year, we expect to advance our first liver and ocular disease programs into IND-enabling studies, while continuing to explore business development opportunities that can accelerate our existing work, enable us to pursue additional programs, and provide access to innovation that can further advance Prime Editing. Over time, we believe the modularity of the Prime Editing platform will allow us to quickly build on our current efforts, unlocking opportunities across a

Read More ...

Eguana Provides Business and Financial Updates

Calgary, Alberta–(Newsfile Corp. – February 7, 2024) – Eguana Technologies Inc. (TSXV: EGT) (OTCQB: EGTYF) (“Eguana” or the “Company“), a leading developer and manufacturer of high-performance energy storage systems, is pleased to provide various business and financial updates.

Financial Update

The Company continues to take prudent action towards navigating a softer than expected renewable energy sector, which has underperformed due to decreased consumer spending related to inflation, high-interest rates, and increased dealer fees. In North America, renewable markets are drastically lower than forecast, and the timing of market recovery is forecasted for the second half of 2024.

In response, the Company furloughed staff in North America before the December Holiday break, with most staff on leave through January and February, and transferred certain personnel into sales positions within our USA sales channel partner. As previously outlined, the Company also rationalized staff in October 2023, with a global headcount reduction of approximately 22 percent. Associated savings related to the North American business, are projected at approximately $2.1M for 2024. Operations in Europe and Australia, where market conditions are significantly better than North America, remain unaffected by the furlough. With functional areas restructured and a priority focus on near-term opportunities, management does not anticipate any near or mid-term impact on operational objectives.

To continue managing short term liquidity risk, the Company successfully negotiated the return of obsolete and/or unusable inventory components (the “Inventory Return”) to a major supply partner. The two parties have entered into an agreement whereby the Inventory Return would result in cash payments to Eguana at full landed cost. Based on the agreement, Eguana expects the total Inventory Return to yield approximately $5.0M in value, including approximately $3.8M in cash and approximately $1.2M of credits against the Company’s outstanding accounts payable to the supply partner.

Read More ...

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

BEIJING, Aug. 11, 2023 /PRNewswire/ — CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the quarter ended June 30, 2023. 

Wei-Wu He, Ph.D., CASI’s Chairman and Chief Executive Officer, commented, “We are pleased to report $9.8 million sales revenue for the second quarter of 2023. This is a 15% increase compared to the same period last year and an 18% of increase from the first quarter of 2023.”

Dr. He continued, “Advancement, development, and commercialization of the portfolio remains our strategic focus.  We have achieved a major milestone with our partner Juventas Biotechnology (Tianjin) Co., Ltd. (“Juventas”) on the CNCT-19 CAR-T Cell therapy. CNCT-19’s New Drug Application (NDA) was accepted by National Medical Products Administration (NMPA) in December 2022. We are now diligently preparing for the anticipated CNCT-19 launch in China. We are advancing the clinical development of BI-1206 in combination with rituximab and presently undertaking the enrollment of patients for the second cohort of the phase I trial in China.  We are transitioning the development of CID-103 into China for the malignant hematology indications. In addition, we acquired global rights for CB-5339 from Cleave Therapeutics in July. On August 1st, we announced the transfer of license of Folotyn® in China from Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc.. We continue to advance our portfolio by executing on several milestones as well as bringing in new potential opportunities for synergy in the quarters ahead.”

Second Quarter 2023 Financial Highlights

  • Revenue was $9.8 million for the three months ended June 30, 2023, compared to $8.6 million for the three months ended June 30, 2022.
  • Costs of revenues were
Read More ...

Azitra, Inc. Announces Second Quarter 2023 Financial Results and Business Updates

BRANFORD, Conn., Aug. 14, 2023 /PRNewswire/ — Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the second quarter ended June 30, 2023.

Francisco Salva, Chief Executive Officer of Azitra, commented, “We are extremely pleased with the exciting recent progress at Azitra, and we are thrilled to have closed on our initial public offering in June. This year, we have demonstrated the potential of our regulatory, manufacturing, and clinical capabilities that resulted in a new IND for ATR-12 for a Phase 1b clinical trial in Netherton syndrome. Additionally, we are very pleased with the recent progress of our platform and collaboration with Bayer.”

Recent Business Highlights

  • Completed an initial public offering: In June, the Company raised $7.5 million in gross proceeds in an initial public offering before deducting underwriting discounts and offering expenses.

  • Announced key appointments to executive team and board of directors: The Company made several key appointments during recent months, including Travis Whitfill as Chief Operating Officer and Barbara Ryan and John Schroer to its board of directors.

  • Obtained IND clearance of ATR-12 for a Phase 1b clinical trial in Netherton syndrome

Financial Results for the Three Months Ended June 30, 2023

  • Cash and cash equivalents: As of June 30, 2023, the Company had cash and cash equivalents of $6.3 million, which includes the proceeds from an initial public offering in June 2023.

  • Service Revenue – Related Party: The Company generated $172,000 of service revenue during the three months ended June 30, 2023 compared to service revenue of $85,000 for the comparable period in 2022. The increase of $87,000 in service revenue is attributable to an increase in the amount of reimbursable development costs incurred in 2023.

  • Research and

Read More ...

KORU Medical Systems, Inc. Announces Preliminary Second Quarter 2023 Revenues and Provides Business, Outlook and Executive Updates

MAHWAH, N.J., August 02, 2023–(BUSINESS WIRE)–KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced preliminary unaudited revenues for the second quarter 2023 and provided business, outlook and executive updates.

The Company reported total net revenues for the second quarter 2023 of approximately $6.9 million, representing growth of approximately 6% compared to the prior year period. Domestic Core revenues increased approximately 8%, International Core revenues increased approximately 17%, and Novel Therapies revenues declined approximately 28% compared to the prior year period.

Full year 2023 net revenues are now expected to be between $31 million and $32.5 million, representing revenue growth in the range of 11%-17% from the prior year. The Company’s guidance for full year 2023 has been updated to reflect a Q2 2023 decline in the U.S. subcutaneous immunoglobulin market, resulting in a change of KORU Medical’s outlook on underlying U.S core market growth assumption from 10% to the mid-single digit range. In addition, the Company’s guidance reflects a change in timing of Novel Therapies revenues.

The Company’s cash balance was $11.7 million as of June 30, 2023, and it is reaffirming an expected end of year cash balance greater than $10.0 million and full year gross margin between 58-60%, and 60-62% exit rate.

“I am pleased our U.S. revenue growth significantly exceeded the overall U.S. market in the quarter and we saw continued strength in our international business,” said Linda Tharby, KORU Medical’s President and CEO. “The foundation of our business remains sound, and we see continued progress this quarter in Novel Therapies collaborations, with a new deal being signed and the early submission

Read More ...

Cost of living – latest updates: Supermarket to ‘lovebomb’ shoplifters; house prices fall at fastest rate in 12 years | UK News

The excitement of getting away from it all when booking a holiday means travel insurance can sometimes become an afterthought.

But the policy could end up saving you a mountain of stress if the worst were to happen on your trip.

A poll of 800 claimants by consumer champion Which? reveals the most common types of travel insurance claim:

Medical costs

The highest proportion of claims made by travellers in the past two years have been for medical cover, Which? found.

Holidaymakers can benefit from protection under the Global Health Insurance Card (GHIC) scheme when travelling to many European countries – this means you can get emergency treatment at no higher cost than if you were a resident.

Costs covered by insurance may also include travel between hospitals or back to the UK where needed.

Cancellation

Cancellation cover was close behind medical costs, at 27% of claims.

Insurers could reimburse you if you have to suddenly cancel your journey before you go, depending on the reason.

This element of travel insurance is why it’s important to find a policy that works for you as soon as you book the holiday – but check that the cancellation cover offered is right for your trip.

Transport delays

A holiday affected by transport delays could be grounds for an insurance claim – with most policies offering some cover for this reason.

The poll by Which? found that 25% of claimants surveyed used this feature.

Delay cover can be for the cost of reimbursing food and accommodation costs while waiting for transport issues to be sorted, or “missed departure” cover.

Not all insurers will offer this however – so check the small print.

Lost possessions

Some 21% of claimants made a claim after their luggage was lost.

The vast majority of insurers offer cover

Read More ...

Google Releases 2023 Ads Safety Report and Search Updates

Google unveiled two bulletins about Google Advertisements and Google Research this week.

If you have not by now, it’s time you catch up with the most recent information from the world’s most preferred search engine.

Let’s dive in.

2023 ads basic safety report produced

On Wednesday, Google launched the 2023 version of their once-a-year Advertisements Protection Report, which will take a deeper search at how they have produced a safer knowledge for consumers in the ad ecosystem in the past 12 months. Google also introduced a brand name new transparency instrument named the Advertisements Transparency Centre, which will be a entirely searchable repository of the world advertisements served from confirmed advertisers. 

Critical Insights from the 2023 Adverts Basic safety Report:

  • Google blocked or removed above 5.2 billion adverts for violating its insurance policies. That’s a lot more than 9,000 adverts for every minute.

  • Google restricted more than 4.3 billion advertisements. 

  • Google blocked around 17 million advertisements related to the war in Ukraine underneath our delicate celebration coverage.

  • Google suspended much more than 6.7 million advertiser accounts for egregious policy violations.

  • Google removed adverts from over 1.5 billion pages final year. 

  • Google included or current 29 policies for the two advertisers and publishers in 2022. 

New fact-checking equipment on Google Lookup

With International Fact-Checking Day (April 2) approaching, Google thinks it’s an important time to take into account facts literacy and misinformation on line. The enterprise states that every person should be empowered with the resources they need to come across information they can have confidence in, which is why it is highlighting equipment and functions obtainable on Lookup to support people today examine the information and facts they occur throughout on the web. A lot more facts about the new Research capabilities can be identified in this blog site article

Read More ...

Ukraine war – live updates today: Russian cruise missile shipment destroyed in Crimea, says Kyiv

Xi Jinping arrives in Moscow to meet Putin for state visit

A shipment of Russian cruise missiles has been destroyed in Russia-occupied Crimea, officials from Ukraine’s defence ministry have said.

“An explosion in the city of Dzhankoy in the north of the temporarily occupied Crimea destroyed the Russian Kalibr NK cruise missiles during their transportation by rail,” the ministry said, though it did not claim responsibility for the attack on Russia’s stockpile.

The explosion, if confirmed, is the first such Ukrainian attack on Russian munitions on Crimean soil.

It comes as Vladimir Putin met his Chinese counterpart Xi Jinping for two days of talks in Moscow. The two presidents called each other “dear friend” as they shook hands at the outset of the latter’s first state visit to Moscow in four years.

The high-level diplomatic visit comes just days after the International Criminal Court (ICC) issued a warrant for Mr Putin’s arrest over war crimes in Ukraine.

The pair held informal one-on-one talks yesterday as well as enjoying a seven-course state banquet, and will today hold further discussions involving their full delegations. Mr Xi has invited Mr Putin to visit China later this year.

1679374069

Shipment of Russian cruise missiles destroyed in Crimea, says Ukraine

An explosion in Russia-occupied Crimea has destroyed a shipment of Russian cruise missiles, officials from Ukraine’s defence ministry said yesterday.

“An explosion in the city of Dzhankoy in the north of the temporarily occupied Crimea destroyed the Russian Kalibr NK cruise missiles during their transportation by rail,” the ministry said, though it did not claim responsibility for the attack on Russia’s stockpile.

It

Read More ...

H3N2 virus LIVE Updates: Assam reports its first case of H3N2 virus

!1 New UpdateClick here for latest updates

Maharashtra farmers march

Discussion held on all issues. 40-50% of issues have been resolved and the rest will be resolved after meeting with CM, Dy CM tomorrow: Maharashtra Minister Atul Save after meeting protesting farmers’ delegation.

Former Los Angeles Mayor Eric Garcetti’s nomination to be Ambassador to India confirmed by US Senate

The Senate voted 52-42 advancing Garcetti’s nomination to be US Ambassador to India.

4 Australian tourists kept under observation at hospital in Jaipur as precautionary measure after they test positive for coronavirus: Officials

2024 elections

BJP’s minority morcha launches year-long Muslim outreach programme with focus on Muslim-dominated districts in UP, Bihar, West Bengal, Kerala and Telangana.

There are 32 patients admitted in Mumbai, out of which 4 are admitted with H3N2 and 28 with H1N1

All of these patients are currently in stable condition: BMC.

HSBC offers Gift City option to Indian startups looking to transfer funds from Silicon Valley Bank

BJP MP Nishikant Dubey demands constitution of special parliamentary committee to inquire into Congress leader Rahul Gandhi’s “contemptuous” remarks and consider if he should be expelled from House

Delhi CM Kejriwal says people will get uninterrupted water supply during summer, asks officials to minimise wastage, curb supply chain problems

Plea seeking formation of National Commission for Men moved in Supreme Court

Delhi CM Kejriwal says people will get uninterrupted water supply during summer, asks officials to minimise wastage, curb supply chain problems

On 14 March, in the morning, the Russian airspace control systems detected an American MQ-9 unmanned aerial vehicle flying over the Black Sea near the Crimean Peninsula in the direction of the state border of the Russian Federation: Russian Defence Ministry

Fighter jets of the air defence force on duty scrambled to identify the intruder. As

Read More ...

2022 Year in Review – legal updates in Canadian marketing, advertising and product compliance

2022 proved to be an interesting year in the advertising, marketing and product compliance space in Canada. From changes to labelling requirements for foods and natural health products, amendments to Canada’s Competition Act to address drip pricing, an increased focus on environmental and sustainability claims, to changes to privacy legislation and French language requirements, Canada has seen a number developments. This article is not an exhaustive list of changes in Canada but highlights certain key matters.

Product Labelling

Front of package nutrition labelling for food products

On July 20, 2022 amendments to the Food and Drug Regulations came into force relating to a new mandatory front-of-package nutrition symbol on all prepackaged foods high in sodium, sugars or saturated fat. Health Canada has released online technical guidance and a backgrounder on the use of the nutrition symbol, which are incorporated into the legislation by reference and which manufacturers will be required to follow.

The nutrition symbol is black and white, depicts a magnifying glass, and identifies if the food is high in sodium, sugars or saturated fat or a combination of these.

Notably, certain foods are not required to display the symbol, if they can rely on the nutrient-specific, technical or practical exemptions identified in the Regulations. Manufacturers will not be required to demonstrate compliance with these changes until January 1, 2026, but may choose to update their packaging sooner. For more information, please see our prior article on this topic.

Changes to natural health products labelling requirements

Following an increase in the use of natural health products (“NHPs”) among Canadians, Health Canada released the Regulations Amending the Natural Health Products Regulations (the “Amending Regulations”), which came into force on June 21, 2022. The Amending Regulations introduce enhanced obligations regarding both content and format of NHP labels.

Read More ...